Genomic tug of war could boost cancer therapy

Wilmot Cancer Institute researchers have uncovered a "g myeloid tug of war" in animal studies that could influence how well certain patients respond to decitabine.

H2A.Z binds DNA loosely, helping to turn on nearby genes, helping the ca Wilmot Cancer Institute pes of cancer have very high levels of H2a.Z, which may help them overcome this drug's effects.

The same effect was seen with a toxic chemical, called TDCIPP, which is widely used in flame retardant Development, Wilmot span class="summaryFeed_highLightText__NxlGi">Meng Murphy first Murphy TDCIPP TDCIPP Two years ago t__NxlGi">Meng Murphy Patrick Murphy me PhD l Health Science CenterBiomedical Genetics "summaryFeed_hig the University of Rochester Medical Center s="summaryFeed_ Wilmot's Genetics, Epigenetics span> first PhD Fanju Meng Murphy